Seattle Genetics (SGEN) Reports Q2 EPS of $0.47, Revenues Beat; Offers FY18 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Seattle Genetics (SGEN) PT Raised to $79 at Needham & Company
July 27, 2018 12:22 PM EDTNeedham & Company raised its price target on Seattle Genetics (NASDAQ: SGEN) to $79.00 (from $74.00) while maintaining a Buy rating.
Analyst Chad Messer commented, "Seattle handily beat Street consensus with 2Q:18 ADCETRIS sales of $122M, higher than our $109M and similar Street... More
Seattle Genetics (SGEN) PT Raised to $64 at Cowen
July 27, 2018 11:29 AM EDTCowen raised its price target on Seattle Genetics (NASDAQ: SGEN) to $64.00 (from $54.00) while maintaining a Outperform rating
Analyst Boris Peaker noted strength was driven by strong adoption in the frontline HL by community docs, although he said the recent stock run-up factors in this stronger uptake.
... MoreSeattle Genetics (SGEN) PT Raised to $81 at SunTrust Robinson Humphrey
July 27, 2018 8:05 AM EDTSunTrust Robinson Humphrey raised its price target on Seattle Genetics (NASDAQ: SGEN) to $81.00 (from $80.00) while maintaining a Buy rating.
Analyst Yatin Suneja commented, "Adcetris surprised with another stronger than expected 2Q18 sales (+14%/$14.8MM vs. consensus), on robust uptake in frontline (1L) cHL.... More
Seattle Genetics (SGEN) PT Raised to $80 at Barclays
July 27, 2018 4:45 AM EDTBarclays raised its price target on Seattle Genetics (NASDAQ: SGEN) to $80.00 (from $74.00) while maintaining a Overweight rating.
... More